Skip to main content

CISA Loses Nearly All Top Officials

3 months 2 weeks ago
Multiple readers shared the following report about the executive departures at CISA: Virtually all of the top officials at the Cybersecurity and Infrastructure Security Agency (CISA) have departed the agency or will do so this month, according to an email obtained by Cybersecurity Dive, further widening a growing void in expertise and leadership at the government's lead cyber defense force at a time when tensions with foreign adversaries are escalating. Five of CISA's six operational divisions and six of its 10 regional offices will have lost top leaders by the end of the month, the agency's new deputy director, Madhu Gottumukkala, informed employees in an email on Thursday. [...] The exits of these leaders could undermine the efficiency and strategic clarity of CISA's partnerships with critical infrastructure operators, private security firms, foreign allies, state governments and local emergency managers, experts say.

Read more of this story at Slashdot.

msmash

Empire of office workers strikes back against RTO mandates

3 months 2 weeks ago
The rebellion grows and it seems resistance is not futile

Despite high-profile calls for employees to get their butts back behind their desks in a traditional workplace setting, more people - at least in the UK - are ignoring return-to-office mandates, a study has found.…

Paul Kunert

Ex-Meta exec: Copyright consent obligation = end of AI biz

3 months 2 weeks ago
Nick Clegg, former politico and Zuckcorp policy Prez, seems confused, can Reg readers help him?

Former British deputy PM and Meta apologist Sir Nick Clegg says that forcing AI companies to ask for the permission of copyright holders before using their content would destroy the AI industry overnight.…

Dan Robinson

GLP-1 Drug Use Surges 600% as 2% of Americans Take Weight-Loss Medications

3 months 2 weeks ago
An anonymous reader shares a report: More than 2% of Americans are taking the blockbuster class of GLP-1 drugs for overweight or obesity, up nearly 600% over six years, according to a report from FAIR Health given to Axios first. The data from FAIR Health's repository of over 51 billion commercial healthcare claim records shows the explosion in use of the drugs specifically for weight loss -- roughly half of all users. In all, roughly 4% of Americans were taking GLP-1 drugs in 2024 for either overweight, obesity or Type 2 diabetes (their original approved use). The data shows Novo Nordisk's Ozempic is still by far the most commonly taken GLP-1, followed by Eli Lilly's Mounjaro. The percentage of adults who were prescribed a GLP-1 drug but did not have bariatric surgery increased from 2.5% in 2019 to 11.2% in 2024 while the the percentage of adult patients who had bariatric surgery decreased 41.8%.

Read more of this story at Slashdot.

msmash